| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Novartis India Limited (NSE: NOVARTIND)
NOVARTIND Technical Analysis
3
| As on 12th Aug 2022 NOVARTIND SHARE Price closed @ 707.95 and we RECOMMEND Buy for LONG-TERM with Stoploss of 706.41 & Buy for SHORT-TERM with Stoploss of 647.48 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NOVARTINDSHARE Price
| Open | 707.00 | Change | Price | % |
| High | 713.80 | 1 Day | 4.60 | 0.65 |
| Low | 704.00 | 1 Week | -6.20 | -0.87 |
| Close | 707.95 | 1 Month | 40.50 | 6.07 |
| Volume | 12445 | 1 Year | -119.15 | -14.41 |
| 52 Week High 1048.90 | 52 Week Low 546.00 | ||||
NSE INDIA Most Active Stocks
| ZOMATO | 61.75 | 6.65% |
| TATASTEEL | 112.65 | 3.25% |
| IDEA | 8.70 | 0.58% |
| GTLINFRA | 1.40 | 7.69% |
| YESBANK | 15.30 | -0.65% |
| SUZLON | 7.55 | -1.95% |
| JPPOWER | 7.50 | -4.46% |
| ONGC | 139.20 | 4.82% |
| SAIL | 81.60 | 3.49% |
| IDFCFIRSTB | 45.10 | -0.33% |
NSE INDIA Top Gainers Stocks
| TIMESGTY | 61.00 | 88.56% |
| EUROTEXIND | 10.05 | 76.32% |
| SCAPDVR | 12.90 | 30.96% |
| NEXTMEDIA | 6.35 | 23.30% |
| WILLAMAGOR | 24.90 | 20.00% |
| DFMFOODS | 252.40 | 19.99% |
| EROSMEDIA | 28.15 | 18.53% |
| AMDIND | 71.45 | 17.42% |
| SANGHIIND | 43.50 | 12.69% |
| MINDTECK | 151.10 | 12.47% |
NSE INDIA Top Losers Stocks
| NOVARTIND Daily Charts |
NOVARTIND Intraday Charts |
Whats New @ Bazaartrend |
NOVARTIND Free Analysis |
|
|
NOVARTIND Important Levels Intraday
| RESISTANCE | 726.83 |
| RESISTANCE | 720.78 |
| RESISTANCE | 717.03 |
| RESISTANCE | 713.29 |
| SUPPORT | 702.61 |
| SUPPORT | 698.87 |
| SUPPORT | 695.12 |
| SUPPORT | 689.07 |
NOVARTIND Target August 2022
| 4th UP Target | 930.09 |
| 3rd UP Target | 847.46 |
| 2nd UP Target | 796.39 |
| 1st UP Target | 745.32 |
| 1st DOWN Target | 599.58 |
| 2nd DOWN Target | 548.51 |
| 3rd DOWN Target | 497.44 |
| 4th DOWN Target | 414.81 |
NOVARTIND Weekly Target
| 4th UP Target | 951.36 |
| 3rd UP Target | 875.29 |
| 2nd UP Target | 828.26 |
| 1st UP Target | 781.24 |
| 1st DOWN Target | 647.06 |
| 2nd DOWN Target | 600.04 |
| 3rd DOWN Target | 553.01 |
| 4th DOWN Target | 476.94 |
NOVARTIND Target2022
| 4th UP Target | 1870.64 |
| 3rd UP Target | 1519.65 |
| 2nd UP Target | 1302.69 |
| 1st UP Target | 1085.73 |
| 1st DOWN Target | 466.67 |
| 2nd DOWN Target | 249.71 |
| 3rd DOWN Target | 32.75 |
| 4th DOWN Target | -318.24 |
Novartis India Limited ( NSE INDIA Symbol : NOVARTIND )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NOVARTIND Synopsis Technicals View
| 50 Day EMA |
N/A (Short Term) |
N/A | |
| 100 Day EMA | N/A (Mid Term) | N/A | |
| 200 Day EMA | N/A (Long Term) | N/A | |
| MACD (12 26 9) | N/A | N/A | |
| RSI (14) | N/A | N/A | |
| MFI (14) | N/A | N/A | |
| CCI (20) | N/A | N/A | |
| WILLIAM %R (14) | N/A | N/A | |
| ADX (14) | N/A | N/A | |
| PSAR | N/A | N/A | |
| 10 Day Avg Volume | N/A | ||
NOVARTIND Other Details
| Segment | EQ | |
| Market Capital | 18732115968.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
NOVARTIND Address
 |
||
NOVARTIND Latest News
NOVARTIND Business Profile
Novartis India Limited operates as a healthcare company in India. It offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences, as well as generics products in the areas of gynecology, anti-TB, and anti-infectives. The company provides central nervous system products under the Tegrital and Exelon brands; pain and inflammation products under the Voveran brand; and transplantation/immunology products under the Simulect, Certican, Myfortic, and Sandimmun Neoral brands. The company was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG. Address: Inspire BKC, G Block, Mumbai, India, 400051
© 2005-2021 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service